Effects of arginine vasopressin on the transcriptome of prefrontal cortex in autistic rat model

J Cell Mol Med. 2022 Nov;26(21):5493-5505. doi: 10.1111/jcmm.17578. Epub 2022 Oct 14.

Abstract

Our previous studies have also demonstrated that AVP can significantly improve social interaction disorders and stereotypical behaviours in rats with VPA-induced autism model. To further explore the mechanisms of action of AVP, we compared the PFC transcriptome changes before and after AVP treatment in VPA-induced autism rat model. The autism model was induced by intraperitoneally injected with VPA at embryonic day 12.5 and randomly assigned to two groups: the VPA-induced autism model group and the AVP treatment group. The AVP treatment group were treated with intranasal AVP at postnatal day 21 and for 3 weeks. The gene expression levels and function changes on the prefrontal cortex were measured by RNA-seq and bioinformatics analysis at PND42 and the mRNA expression levels of synaptic and myelin development related genes were validated by qPCR. Our results confirmed that AVP could significantly improve synaptic and axon dysplasia and promote oligodendrocyte development in the prefrontal cortex in VPA-induced autism models by regulating multiple signalling pathways.

Keywords: arginine vasopressin; autism spectrum disorder; neurodevelopmental; oligodendrocyte; prefrontal cortex; synapse.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arginine Vasopressin* / metabolism
  • Arginine Vasopressin* / pharmacology
  • Autistic Disorder* / chemically induced
  • Autistic Disorder* / drug therapy
  • Autistic Disorder* / genetics
  • Disease Models, Animal
  • Prefrontal Cortex / metabolism
  • Rats
  • Transcriptome / genetics
  • Valproic Acid / adverse effects

Substances

  • Arginine Vasopressin
  • Valproic Acid